journal
MENU ▼
Read by QxMD icon Read
search

Gynecologic Oncology

journal
https://www.readbyqxmd.com/read/28716308/unexpected-locations-of-sentinel-lymph-nodes-in-endometrial-cancer
#1
Jeffrey How, Irina Boldeanu, Susie Lau, Shannon Salvador, Emily How, Raphael Gotlieb, Jeremie Abitbol, Ajay Halder, Zainab Amajoud, Stephan Probst, Sonya Brin, Walter Gotlieb
INTRODUCTION: To evaluate the anatomical location of sentinel lymph nodes (SLN) following intra-operative cervical injection in endometrial cancer. METHODS: All consecutive patients with endometrial cancer undergoing sentinel lymph node mapping were included in this prospective study following intra-operative cervical injection of tracers. Areas of SLN detection distribution were mapped. RESULTS: Among 436 patients undergoing SLN mapping, there were 1095 SLNs removed, and 7...
July 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28716307/should-epithelial-ovarian-carcinoma-metastatic-to-the-inguinal-lymph-nodes-be-assigned-stage-ivb
#2
Dimitrios Nasioudis, Eloise Chapman-Davis, Melissa K Frey, Thomas A Caputo, Steven S Witkin, Kevin Holcomb
OBJECTIVE: According to the revised FIGO staging system women with ovarian carcinoma and inguinal lymph node (LN) metastases, formerly stage III, are now considered stage IVB. In this study we compare their survival to that of women with stage III and stage IV disease. METHODS: Women diagnosed with epithelial ovarian carcinoma were drawn from the Surveillance, Epidemiology, and End Results database (2004-2013). Four groups were formed: group 1 (stage IV due to positive inguinal nodes), group 2 (stage III with positive para-aortic/pelvic nodes), group 3 (stage IV with positive distant nodes) and group 4 (stage IV with distant metastases)...
July 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28716306/tertiary-cytoreductive-surgery-in-recurrent-epithelial-ovarian-cancer-a-multicentre-mito-retrospective-study
#3
F Falcone, G Scambia, P Benedetti Panici, M Signorelli, G Cormio, G Giorda, S Bogliolo, M Marinaccio, F Ghezzi, E Rabaiotti, E Breda, G Casella, F Fanfani, V Di Donato, U Leone Roberti Maggiore, S Greggi
OBJECTIVES: To evaluate the impact of tertiary cytoreductive surgery (TCS) on survival in recurrent epithelial ovarian cancer (EOC), and to determine predictors of complete cytoreduction. METHODS: A multi-institutional retrospective study was conducted within the MITO Group on a 5-year observation period. RESULTS: A total of 103 EOC patients with a ≥6month treatment-free interval (TFI) undergoing TCS were included. Complete cytoreduction was achieved in 71 patients (68...
July 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28709705/phase-ii-trial-of-neoadjuvant-chemotherapy-followed-by-chemoradiation-in-locally-advanced-cervical-cancer
#4
Carla Rameri Alexandre Silva de Azevedo, Luiz Cláudio Santos Thuler, Maria Júlia Gonçalves de Mello, Jurema Telles de Oliveira Lima, Ana Luiza Fassizoli da Fonte, Diógenes Fernando Santos Fontão, Vandré Cabral Gomes Carneiro, Tien Man Cabral Chang, Carlos Gil Ferreira
OBJECTIVE: Cervical cancer is a global public health challenge. Since 1999, platin based chemoradiation (CRT) is the standard treatment for those patients with locally advanced disease. However, this population still has a dismal prognosis and, alternatives approaches such as adjuvant chemotherapy are controversial, especially because of increased toxicity. Neoadjuvant chemotherapy (NACT) could be an option for more intensive treatment with manageable toxicity. METHODS: A phase II, prospective, non-randomized trial was conducted at a reference center in Recife, Brazil...
July 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28709704/epigenetic-silencing-of-mlh1-in-endometrial-cancers-is-associated-with-larger-tumor-volume-increased-rate-of-lymph-node-positivity-and-reduced-recurrence-free-survival
#5
Casey M Cosgrove, David E Cohn, Heather Hampel, Wendy L Frankel, Dan Jones, Joseph P McElroy, Adrian A Suarez, Weiqiang Zhao, Wei Chen, Ritu Salani, Larry J Copeland, David M O'Malley, Jeffrey M Fowler, Ahmet Yilmaz, Alexis S Chassen, Rachel Pearlman, Paul J Goodfellow, Floor J Backes
OBJECTIVES: To determine the relationship between mismatch repair (MMR) classification and clinicopathologic features including tumor volume, and explore outcomes by MMR class in a contemporary cohort. METHODS: Single institution cohort evaluating MMR classification for endometrial cancers (EC). MMR immunohistochemistry (IHC)±microsatellite instability (MSI) testing and reflex MLH1 methylation testing was performed. Tumors with MMR abnormalities by IHC or MSI and MLH1 methylation were classified as epigenetic MMR deficiency while those without MLH1 methylation were classified as probable MMR mutations...
July 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28709703/extent-of-lymphovascular-space-invasion-may-predict-lymph-node-metastasis-in-uterine-serous-carcinoma
#6
Yushen Qian, Erqi L Pollom, Chika Nwachukwu, Kira Seiger, Rie von Eyben, Ann K Folkins, Elizabeth A Kidd
OBJECTIVES: Emerging evidence suggests that extent of lymphovascular space invasion (LVSI) predicts for risk of lymph node metastasis in endometrioid uterine cancers. However, this correlation remains unknown in the setting of uterine serous carcinoma (USC). We sought to examine the association between extent of LVSI and other histopathologic characteristics with risk of nodal metastasis for women with USC. MATERIALS/METHODS: Pathological data from all cases of uterine serous carcinoma between July 1998 to July 2015 at our institution were reviewed...
July 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28705409/clinical-benefit-and-risk-of-death-with-endocrine-therapy-in-ovarian-cancer-a-comprehensive-review-and-meta-analysis
#7
Laura Paleari, Sara Gandini, Nicoletta Provinciali, Matteo Puntoni, Nicoletta Colombo, Andrea DeCensi
BACKGROUND: Steroid hormones promote epithelial ovarian cancer (EOC) growth and their receptor expression is associated with disease outcome. Hormone therapy is frequently used in pretreated EOC, but the magnitude of activity overall and by specific agents or tumor characteristics is unknown. METHODS: Clinical Benefit Rates (CBR) and deaths from clinical trials of endocrine agents were meta-analyzed. Summary estimates of CBR (SCBR) and Odd Ratio for death (SOR) were calculated according with type of drug, ER and PgR status, platinum resistance, line of therapy, tumor grade and tamoxifen dose...
July 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28705408/superior-in-vitro-and-in-vivo-activity-of-trastuzumab-emtansine-t-dm1-in-comparison-to-trastuzumab-pertuzumab-and-their-combination-in-epithelial-ovarian-carcinoma-with-high-her2-neu-expression
#8
Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Gary Altwerger, Jonathan D Black, Katherine Dugan, Francesca Pettinella, Alice Masserdotti, Francesco Riccio, Anna Bianchi, Luca Zammataro, Christopher de Haydu, Natalia Buza, Pei Hui, Serena Wong, Gloria S Huang, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz, Alessandro D Santin
BACKGROUND: Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. The objective of this study was to compare the anti-tumor activity of HER2/neu-targeting monoclonal antibodies, trastuzumab (T), pertuzumab (P), combination of trastuzumab and pertuzumab (T+P) and trastuzumab-emtansine (T-DM1) in EOC with high HER2/neu expression. METHODS: Primary EOC cell lines were established and cell blocks were analyzed for HER2/neu expression. Cytostatic, apoptotic and antibody-dependent cell-mediated cytotoxicity (ADCC) activities of T, P, T+P and T-DM1 were evaluated in vitro...
July 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28698010/compliance-with-research-standards-within-gynecologic-oncology-fellowship-a-gynecologic-oncology-fellowship-research-network-gofrn-study
#9
Laura J Moulton, Chad M Michener, Kimberly Levinson, Lauren Cobb, Jill Tseng, Amelia Jernigan
OBJECTIVES: Participation in clinical and basic science research is emphasized in gynecologic oncology training. We sought to identify trends in adherence to expected research practices and reasons for non-adherence among gynecologic oncology fellows. METHODS: An anonymous 31-question online survey assessing academic behaviors, including IRB compliance, authorship assignment, data sharing, and potential barriers to non-adherence was distributed to all SGO gynecologic oncology fellow members in July 2016...
July 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28698009/a-randomised-open-label-phase-2-study-of-the-ido1-inhibitor-epacadostat-incb024360-versus-tamoxifen-as-therapy-for-biochemically-recurrent-ca-125-relapse-only-epithelial-ovarian-cancer-primary-peritoneal-carcinoma-or-fallopian-tube-cancer
#10
Rebecca Kristeleit, Irina Davidenko, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko, Michael J Goodheart, Vera Gorbunova, Carol A Penning, Jack G Shi, Xiangdong Liu, Robert C Newton, Yufan Zhao, Janet Maleski, Lance Leopold, Russell J Schilder
OBJECTIVE: Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme inhibitor epacadostat versus tamoxifen in patients with biochemical-only recurrence (CA-125 elevation) following complete remission after first-line chemotherapy for advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. METHODS: In this open-label, phase 2 study (NCT01685255), patients were randomised 1:1 to epacadostat 600mg or tamoxifen 20mg twice daily for successive 28-day cycles and stratified by time since completion of first-line chemotherapy to first CA-125 elevation (3 to <12 or ≥12months)...
July 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28698008/prognostic-significance-of-tumor-associated-macrophages-in-ovarian-cancer-a-meta-analysis
#11
REVIEW
Xia Yuan, Jing Zhang, Dan Li, Ye Mao, Fei Mo, Wei Du, Xuelei Ma
OBJECTIVE: The role of tumor-associated macrophages (TAMs) in tumor microenvironment remains controversial due to the two different polarized subsets of TAMs. Here, we performed a meta-analysis to evaluate the correlation between subpopulations of TAMs and clinical outcomes in patients with ovarian cancer. METHODS: A comprehensive search in PUBMED/Medline and EMBASE databases was performed. The association between TAMs and patient prognosis of ovarian cancer was estimated with hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) using a random-effect model...
July 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28693948/the-american-society-of-clinical-oncology-2017-annual-meeting-a-review-and-summary-of-selected-abstracts
#12
Bobbie J Rimel, Steven J Gibson, Daniele A Sumner, Bradley J Monk
No abstract text is available yet for this article.
July 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28689668/factors-influencing-clinical-trial-enrollment-among-ovarian-cancer-patients
#13
Molly M Greenwade, Kathleen N Moore, Jessica M Gillen, Kai Ding, Michelle R Rowland, Aleia K Crim, Bailey Kleis, Camille C Gunderson
OBJECTIVE: To characterize patients who did not enroll on a clinical trial and identify barriers that may limit enrollment among patients with advanced epithelial ovarian cancer (EOC) presenting for first-line chemotherapy. METHODS: We conducted a retrospective review of patients diagnosed with stage II-IV EOC from 10/2009-4/2013, a time period during which multiple trials were available to all EOC patients, including optimally debulked, suboptimally debulked, or undergoing neoadjuvant chemotherapy...
July 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28689667/is-hormonal-therapy-effective-in-advanced-endometrial-cancer-a-systematic-review-and-meta-analysis
#14
REVIEW
Josee-Lyne Ethier, Danielle N Desautels, Eitan Amir, Helen MacKay
BACKGROUND: Hormonal therapy (HT) is used commonly in the treatment of advanced endometrial cancer (EC). However, a 2010 Cochrane Review did not show a survival benefit for HT. Here, we quantify its effects and explore the influence of clinico-pathologic factors and hormone receptor (HR) status on overall response rates (ORR). METHODS: A systematic search of electronic databases identified publications of HT in advanced EC. Data from individual studies reporting ORR, median progression-free (PFS) or overall survival (OS) were weighted by individual study sample size and pooled in a meta-analysis...
July 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28689666/incidence-rates-and-risks-of-diethylstilbestrol-related-clear-cell-adenocarcinoma-of-the-vagina-and-cervix-update-after-40-year-follow-up
#15
Dezheng Huo, Diane Anderson, Julie R Palmer, Arthur L Herbst
OBJECTIVE: Women exposed to diethylstilbestrol (DES) in utero are at increased risk for the development of vaginal and cervical clear cell adenocarcinoma (CCA) at younger age. It is unknown if a second peak will occur in later life, the ages when CCA developed spontaneously in the pre-DES era. The complete epidemiologic curve of CCA has not been reported, yet. METHODS: We reviewed 720 cases of CCA from the CCA registry at the University of Chicago through 2014. Incidence rates and cumulative risks for CCA were calculated based on white women born in the U...
July 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28688523/erratum-to-worldwide-comparison-of-ovarian-cancer-survival-histological-group-and-stage-at-diagnosis-concord-2-gynecol-oncol-144-2017-396-404
#16
Melissa Matz, Michel P Coleman, Helena Carreira, Diego Salmerón, Maria Dolores Chirlaque, Claudia Allemani
No abstract text is available yet for this article.
July 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28688522/porta-hepatis-debulking-procedures-as-part-of-primary-cytoreductive-surgery-for-advanced-ovarian-cancer
#17
Joo-Hyuk Son, Suk-Joon Chang, Hee-Sug Ryu
Tumor involvement of the porta hepatis in advanced ovarian cancer has been considered as the important barrier to optimal cytoreduction [1]. Debulking procedures to the porta hepatis still remain one of significant surgical challenges to gynecologic oncologists in the management of advanced ovarian cancer patients. However, recent series have shown that aggressive porta hepatis debulking procedures are highly effective for complete cytoreduction leaving no gross residual disease and associated with improved survival [2,3]...
July 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28687170/erratum-to-the-histology-of-ovarian-cancer-worldwide-distribution-and-implications-for-international-survival-comparisons-concord-2-gynecol-oncol-144-2017-405-413
#18
Melissa Matz, Michel P Coleman, Milena Sant, Maria Dolores Chirlaque, Otto Visser, Martin Gore, Claudia Allemani
No abstract text is available yet for this article.
July 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28687171/volume-controlled-versus-short-drainage-after-inguinofemoral-lymphadenectomy-in-vulvar-cancer-patients-a-dutch-nationwide-prospective-study
#19
A W Pouwer, F Hinten, J van der Velden, R G V Smolders, B F M Slangen, H J M A A Zijlmans, J IntHout, A G J van der Zee, D Boll, K N Gaarenstroom, H J Arts, J A de Hullu
OBJECTIVE: Inguinofemoral lymphadenectomy for patients with vulvar squamous cell carcinoma is associated with a high incidence of postoperative wound complications, which may be influenced by inguinal drain management. The aim of this nationwide prospective study (MAMBO: Morbidity And Measurement of the BOdy) was to assess the feasibility and the incidence of complications after volume-controlled versus short drainage. METHODS: The MAMBO study consisted of two observational studies in all eight oncology centers in the Netherlands, conducted between 2012 and 2016...
July 4, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28673661/prognostic-impact-of-interleukin-6-expression-in-stage-i-ovarian-clear-cell-carcinoma
#20
Ayako Kawabata, Nozomu Yanaihara, Chie Nagata, Misato Saito, Daito Noguchi, Masataka Takenaka, Yasushi Iida, Hirokuni Takano, Kyosuke Yamada, Masami Iwamoto, Takako Kiyokawa, Aikou Okamoto
OBJECTIVE: Ovarian clear cell carcinoma (OCCC) frequently presents at an early stage. In stage I OCCC, the prognosis differs according to substage. In particular, predictive biomarkers and new treatment strategies are needed for stage IC2/IC3 disease. We investigated tumor biology and prognostic factors for stage I OCCC from a clinicopathological perspective, including the expression of ARID1A and IL-6, which are considered critical for OCCC carcinogenesis. METHODS: A retrospective cohort study of 192 patients with stage I OCCC treated at a single institution was performed...
June 30, 2017: Gynecologic Oncology
journal
journal
23122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"